Objectives: The purposes of our study were to evaluate the effect of intraperitoneal albendazole on tumor growth, ascites formation, and vascular endothelial growth factor (VEGF) mRNA expression, and to assess the synergistic effect of paclitaxel in OVCAR-3-bearing nude mice. Methods: In all, 4 groups of mice were injected intraperitoneally with weekly albendazole (450 mg/kg per week), paclitaxel (30 mg/kg per week), albendazole plus paclitaxel, or normal saline for 4 weeks. Results: Ascitic fluid accumulation (2.47, 2.65, 2.88, and 5.90 mL, respectively) and in ascitic VEGF levels were significantly reduced in the 3 treatment groups compared to the control group (170.83, 229.16, 267, and 1625 pg/mL, respectively). However, complete tumor suppression was more prominent in the paclitaxel group, and VEGF mRNA expression was more strongly inhibited in the albendazole group (P <.05). No synergistic effect of albendazole and paclitaxel was observed. Conclusion: We demonstrated a differential effect of albendazole and paclitaxel in a xenograft model of ovarian carcinoma; albendazole suppressed ascites formation by inhibiting VEGF secretion, and paclitaxel exerted its effects by direct cytotoxicity.
Bibliographical noteFunding Information:
The authors disclosed receipt of the following financial support for the research and/or authorship of this article: The NHIC Ilsan Hospital, the Brain Korea 21 project for medical sciences, Yonsei University, a faculty research grant of Yonsei University College of Medicine for 2007 (6-2007-0179) and National Research Foundation of Korea Grant funded by the Korean Government (2009-0071158).
All Science Journal Classification (ASJC) codes
- Obstetrics and Gynaecology